Cargando…
Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation
BACKGROUND: Post-transplant malignancy (PTM) causes long-term morbidity and mortality in heart transplant (HTx) recipients. However, the detailed characteristics or predictors of PTM are not well-known. We evaluated the incidence, characteristics, long-term outcomes, and predictors of de novo PTM us...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393331/ https://www.ncbi.nlm.nih.gov/pubmed/36003907 http://dx.doi.org/10.3389/fcvm.2022.939275 |
_version_ | 1784771249775312896 |
---|---|
author | Youn, Jong-Chan Kim, Darae Kim, In-Cheol Lee, Hye Sun Choi, Jin-Oh Jeon, Eun-Seok Nishihara, Keith Kransdorf, Evan P. Chang, David H. Kittleson, Michelle M. Patel, Jignesh K. Ramzy, Danny Esmailian, Fardad Kobashigawa, Jon A. |
author_facet | Youn, Jong-Chan Kim, Darae Kim, In-Cheol Lee, Hye Sun Choi, Jin-Oh Jeon, Eun-Seok Nishihara, Keith Kransdorf, Evan P. Chang, David H. Kittleson, Michelle M. Patel, Jignesh K. Ramzy, Danny Esmailian, Fardad Kobashigawa, Jon A. |
author_sort | Youn, Jong-Chan |
collection | PubMed |
description | BACKGROUND: Post-transplant malignancy (PTM) causes long-term morbidity and mortality in heart transplant (HTx) recipients. However, the detailed characteristics or predictors of PTM are not well-known. We evaluated the incidence, characteristics, long-term outcomes, and predictors of de novo PTM using a single center large-volume database. METHODS: We retrospectively analyzed the types and characteristics of de novo PTM in 989 patients who underwent HTx. Univariate and multivariate logistic regression analyses were used for the PTM prediction model. RESULTS: Two hundred and six patients (20.8%) had de novo PTMs (241 cancers) during a median follow-up of 11.5 years. PTM patients were older than non-PTM patients, received immunosuppressive therapy for a longer period, and were more likely to be male and white. Skin cancers were the most frequent types of malignancy (60.6%) followed by prostate (9.5%), lung (7.1%), and breast (4.1%) cancers. Although most cancers (88.8%) were surgically resected at initial presentation, about half (47.3%) recurred or progressed. Patients with skin cancer and non-skin cancer had significantly lower overall survival (P < 0.001) than patients without cancer. Older age (P < 0.001), white race (P = 0.001), and longer time receiving immunosuppressive therapy (P < 0.001) were independent predictors for PTM. CONCLUSION: Older age, white race, and longer administration of immunosuppressive therapies were independent risk factors for PTM, which was associated with increased mortality. Further research is necessary for the prevention and early detection of PTM in HTx recipients. |
format | Online Article Text |
id | pubmed-9393331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93933312022-08-23 Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation Youn, Jong-Chan Kim, Darae Kim, In-Cheol Lee, Hye Sun Choi, Jin-Oh Jeon, Eun-Seok Nishihara, Keith Kransdorf, Evan P. Chang, David H. Kittleson, Michelle M. Patel, Jignesh K. Ramzy, Danny Esmailian, Fardad Kobashigawa, Jon A. Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Post-transplant malignancy (PTM) causes long-term morbidity and mortality in heart transplant (HTx) recipients. However, the detailed characteristics or predictors of PTM are not well-known. We evaluated the incidence, characteristics, long-term outcomes, and predictors of de novo PTM using a single center large-volume database. METHODS: We retrospectively analyzed the types and characteristics of de novo PTM in 989 patients who underwent HTx. Univariate and multivariate logistic regression analyses were used for the PTM prediction model. RESULTS: Two hundred and six patients (20.8%) had de novo PTMs (241 cancers) during a median follow-up of 11.5 years. PTM patients were older than non-PTM patients, received immunosuppressive therapy for a longer period, and were more likely to be male and white. Skin cancers were the most frequent types of malignancy (60.6%) followed by prostate (9.5%), lung (7.1%), and breast (4.1%) cancers. Although most cancers (88.8%) were surgically resected at initial presentation, about half (47.3%) recurred or progressed. Patients with skin cancer and non-skin cancer had significantly lower overall survival (P < 0.001) than patients without cancer. Older age (P < 0.001), white race (P = 0.001), and longer time receiving immunosuppressive therapy (P < 0.001) were independent predictors for PTM. CONCLUSION: Older age, white race, and longer administration of immunosuppressive therapies were independent risk factors for PTM, which was associated with increased mortality. Further research is necessary for the prevention and early detection of PTM in HTx recipients. Frontiers Media S.A. 2022-08-08 /pmc/articles/PMC9393331/ /pubmed/36003907 http://dx.doi.org/10.3389/fcvm.2022.939275 Text en Copyright © 2022 Youn, Kim, Kim, Lee, Choi, Jeon, Nishihara, Kransdorf, Chang, Kittleson, Patel, Ramzy, Esmailian and Kobashigawa. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Youn, Jong-Chan Kim, Darae Kim, In-Cheol Lee, Hye Sun Choi, Jin-Oh Jeon, Eun-Seok Nishihara, Keith Kransdorf, Evan P. Chang, David H. Kittleson, Michelle M. Patel, Jignesh K. Ramzy, Danny Esmailian, Fardad Kobashigawa, Jon A. Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation |
title | Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation |
title_full | Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation |
title_fullStr | Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation |
title_full_unstemmed | Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation |
title_short | Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation |
title_sort | characteristics, outcomes, and predictors of de novo malignancy after heart transplantation |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393331/ https://www.ncbi.nlm.nih.gov/pubmed/36003907 http://dx.doi.org/10.3389/fcvm.2022.939275 |
work_keys_str_mv | AT younjongchan characteristicsoutcomesandpredictorsofdenovomalignancyafterhearttransplantation AT kimdarae characteristicsoutcomesandpredictorsofdenovomalignancyafterhearttransplantation AT kimincheol characteristicsoutcomesandpredictorsofdenovomalignancyafterhearttransplantation AT leehyesun characteristicsoutcomesandpredictorsofdenovomalignancyafterhearttransplantation AT choijinoh characteristicsoutcomesandpredictorsofdenovomalignancyafterhearttransplantation AT jeoneunseok characteristicsoutcomesandpredictorsofdenovomalignancyafterhearttransplantation AT nishiharakeith characteristicsoutcomesandpredictorsofdenovomalignancyafterhearttransplantation AT kransdorfevanp characteristicsoutcomesandpredictorsofdenovomalignancyafterhearttransplantation AT changdavidh characteristicsoutcomesandpredictorsofdenovomalignancyafterhearttransplantation AT kittlesonmichellem characteristicsoutcomesandpredictorsofdenovomalignancyafterhearttransplantation AT pateljigneshk characteristicsoutcomesandpredictorsofdenovomalignancyafterhearttransplantation AT ramzydanny characteristicsoutcomesandpredictorsofdenovomalignancyafterhearttransplantation AT esmailianfardad characteristicsoutcomesandpredictorsofdenovomalignancyafterhearttransplantation AT kobashigawajona characteristicsoutcomesandpredictorsofdenovomalignancyafterhearttransplantation |